Dubow Adam

Average Profitability
<0.0001%
Insider Buys Quantity
0
Insider Buys Sum
$0
Insider Sells Quantity
10
Insider Sells Sum
$1.7M

Insider Activity of Dubow Adam

According to the SEC Form 4 filings, Dubow Adam, being in a position of

  1. GENERAL COUNSEL at Day One Biopharmaceuticals, Inc.,
    оver the last 12 months, has bought 0 shares, and sold 12862 shares for $188,374,
    over all time since 2023-11-16, has bought 0 shares, and sold 18175 shares for $250,483.

The largest sale of all time was on 2021-05-05 and amounted to 6238 shares of Bristol-Myers Squibb Company for $400,542.

Biography of Dubow Adam

No biography is available at this moment.

2024-11-18SaleDay One Biopharmaceuticals, Inc.
DAWN
GENERAL COUNSEL
3,165
0.0032%
$13.21$41,810+2.61%
2024-08-16SaleDay One Biopharmaceuticals, Inc.
DAWN
GENERAL COUNSEL
3,202
0.0038%
$14.00$44,8250%
2024-05-16SaleDay One Biopharmaceuticals, Inc.
DAWN
GENERAL COUNSEL
3,253
0.0037%
$16.08$52,304-13.86%
2024-02-16SaleDay One Biopharmaceuticals, Inc.
DAWN
GENERAL COUNSEL
3,242
0.0037%
$15.25$49,434-7.37%
2023-11-16SaleDay One Biopharmaceuticals, Inc.
DAWN
General Counsel
5,313
0.0061%
$11.69$62,109+22.79%
2021-07-30SaleBristol-Myers Squibb Company
BMY
SVP,ChiefCompliance&EthicsOff.
4,932
0.0002%
$67.90$334,883+0.22%
2021-05-05SaleBristol-Myers Squibb Company
BMY
SVP,ChiefCompliance&EthicsOff.
6,238
0.0003%
$64.21$400,542+2.78%
2020-11-24SaleBristol-Myers Squibb Company
BMY
SVP,ChiefCompliance&EthicsOff.
1,800
<0.0001%
$63.39$114,102+0.57%
2020-05-22SaleBristol-Myers Squibb Company
BMY
SVP,ChiefCompliance&EthicsOff.
6,400
0.0003%
$61.01$390,464+2.67%
2019-12-05SaleBristol-Myers Squibb Company
BMY
Chief Compliance & Ethics Offi
3,480
0.0002%
$58.81$204,659+4.21%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.